Clinical trials: Natriuretic Peptide Brain
Heart Failure, Congestive
A Safety Study Comparing Natrecor (Nesiritide) Versus Dobutamine Therapy for Worsening Congestive Heart Failure
The purpose of this study is to compare the effects on heart rate and ventricular arrhythmias (irregular heart beats) of two doses of Natrecor® (a recombinant form of the natural human peptide normally secreted by the heart in…
- Trial name
- NCT00270400
- Testing
- nesiritide
- Volunteers
- 255 people
- Sponsor
- Scios, Inc.
Heart Failure, Ventricular Dysfunction, Left
Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone
The purpose is to study if HF treatment guided by NTproBNP in addition to clinical symptoms and signs is more effective than treatment guided by clinical symptoms and signs alone in patients with HF and left ventricular systolic…
- Trial name
- NCT00391846
- Testing
- Captopril, Enalapril, Lisinopril
- Where
- 39 sites in Sweden
- Volunteers
- 252 people
- Sponsor
- AstraZeneca
Heart Failure
RISK Stratification Using a Combination of Cardiac Troponin T and Brain Natriuretic Peptide in Patients Receiving CRT-D
The purpose of the study is to identify if the combined use of cardiac troponin enzyme (cTnT) and brain natriuretic peptide (BNP) can predict Heart Failure (HF)improvement and all-cause mortality in patients implanted with…
- Trial name
- RISK (NCT00453622)
- Testing
- Cardiac Resynchronization Therapy-Defibrillator
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Abbott Medical Devices
Post Acute Coronary Syndrome, Myocardial Ischemia
Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome
The purpose of this study is to test the hypothesis that the inhibition of the renin-angiotensin-aldosterone system (RAAS) with the angiotensin receptor blocker valsartan or the renin antagonist aliskiren will improve ventricular…
- Trial name
- NCT00409578
- Testing
- Aliskiren 300 mg, Valsartan 320 mg, Aliskiren/valsartan 300/320 mg
- Where
- 11 sites in United States, Belgium and 9 more
- Volunteers
- 1,101 people
- Sponsor
- Novartis
Heart Failure
REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction
This study is researching an experimental drug called REGN5381 (called "study drug"). The study is focused on patients with heart failure with reduced ejection fraction (ie, the heart is not functioning as well as it should).
- Trial name
- NATRIX-BNP (NCT06237309)
- Testing
- REGN5381
- Where
- 44 sites in United States, Belgium and 10 more
- Volunteers
- 89 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Heart Failure and Reduced Ejection Fraction (HFrEF)
Secondary Use of PARALLEL-HF Data
This study utilized the blood and first morning void (FMV) urine samples from the PARALLEL-HF study (core part). The PARALLEL-HF study (core part) was a multicenter, randomized, double-blind, double-dummy, parallel-group…
- Trial name
- NCT07527767
- Where
- Japan
- Volunteers
- 236 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
Efficacy of Candesartan on Brain Natriuretic Peptide Levels in Subjects With Chronic Heart Failure
The purpose of this study is to determine the effects of Candesartan, once daily (QD), added to ongoing chronic heart disease therapy in measuring brain natriuretic peptide in patients with chronic heart failure.
- Trial name
- CANDHEART (NCT00843154)
- Testing
- Candesartan and standard chronic heart disease therapy, Standard chronic heart disease therapy
- Volunteers
- 571 people
- Sponsor
- Takeda
Congestive Heart Failure, Cardiac Transplantation
Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC
The purposes of this study in United Network for Organ Sharing (UNOS) Status 1B (or country equivalent) cardiac transplant candidates are to assess the safety and efficacy of Natrecor (nesiritide).
- Conditions
- Congestive Heart Failure, Cardiac Transplantation, Renal Insufficiency, Renal Failure
- Trial name
- NCT00338455
- Testing
- Natrecor (nesiritide)+Standard Care+dobutamine or milrinone
- Where
- 14 sites in United States
- Volunteers
- 16 people
- Sponsor
- Scios, Inc.
Transthyretin Amyloid Cardiomyopathy
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
The primary objective of this study is to access the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the total…
- Trial name
- DepleTTR-CM (NCT06183931)
- Testing
- ALXN2220
- Where
- 213 sites in United States, Argentina and 25 more
- Volunteers
- 1,182 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Heart Failure, Congestive, Heart Decompensation
A Study of Two Doses of Intravenous NATRECOR hBNP (Nesiritide) in Patients With Worsening Congestive Heart Failure Who Have Difficulty Breathing at Rest
The purpose of this study is to assess the safety and efficacy of two doses of intravenous NATRECOR® hBNP (a recombinant form of the natural human peptide normally secreted by the heart) versus placebo in the treatment of…
- Trial name
- NCT00288730
- Testing
- nesiritide
- Volunteers
- 127 people
- Sponsor
- Scios, Inc.
Hypertension, Congestive Heart Failure
The VALIDATE Study of Valsartan for Patients With Early Stage Heart Failure
This is a study to evaluate the response of patients with hypertension and early stage heart failure to valsartan.
- Trial name
- NCT00241098
- Testing
- valsartan
- Volunteers
- 37 people
- Sponsor
- Novartis
Diagnostic Tests
AQT90 FLEX NTproBNP (N-terminal Pro-brain Natriuretic Peptide) 2 Test Kit - Reference Interval Study Protocol - China
To establish the reference range of the NTproBNP2 Test Kit (time-resolved immunofluorescence method) in apparently healthy Chinese population.
- Trial name
- NCT06963619
- Volunteers
- 240 people
- Sponsor
- Radiometer Medical ApS
Chronic Heart Failure, High Blood B-type (or Brain) Natriuretic Peptide (BNP) Level
Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24
This study will compare olmesartan medoxomil to candesartan cilexetil in reducing BNP, a prognostic biomarker of heart failure, at week 24
- Trial name
- OLMEBNP (NCT00679484)
- Where
- 11 sites in France, Germany and 1 more
- Volunteers
- 400 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Peripheral Vascular Disease
A Prospective Study to Assess the Screening Value of N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) for the Identification of Patients That Benefit From Additional Cardiac Testing Prior to Vascular Surgery
The purpose of this study is to validate the screening potential of NT-proBNP for the identification of patients scheduled for vascular surgery who would benefit from additional pre-operative cardiac testing.
- Trial name
- NCT00519961
- Testing
- Elecsys®proBNP
- Where
- 2 sites in Ireland, Netherlands
- Volunteers
- 1,800 people
- Sponsor
- Hoffmann-La Roche